Work

P01.03 Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLC

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.01.327

Authors: P. Jänne, R. Rajagopalan, G. Pudussery, P. Shrestha, S. Chen, R. Hodge, Y. Qiu, C. Yu

Institutions: Dana-Farber Cancer Institute, AstraZeneca (United Kingdom), Daiichi Sankyo (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3136093602

Cites:

Cited by:

Related to: 10